Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03356470 · ClinicalTrials.gov registry record
Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 5
- Enrollment target
NCT03356470: Completed study, sponsored by University of Wisconsin, Madison.
NCT03356470 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03356470 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
This study uses molecular imaging and novel immune monitoring to identify a biomarker of response for melanoma patients receiving immunotherapy with anti-PD-1 immunotherapy. Prior to treatment, FDG and FLT PET/CT will be obtained, together with blood and tumor biopsies from each patient. A follow-up FDG and FLT PET/CT will be obtained, together with blood and tumor biopsies, 10-12 weeks after starting treatment with anti-PD-1 antibody. Additional tumor biopsies and blood samples for immune monitoring will be obtained 4-6 weeks after starting treatment with anti-PD-1 antibody as well as 16-18 weeks after starting anti-PD-1 treatment for patients still receiving anti-PD-1 antibody at that time.
Primary Outcome
To correlate baseline and post-treatment molecular imaging biomarkers of response to immunotherapy with anti-PD-1 with antitumor response based on analysis of the FDG-to-FLT PET/CT ratio in melanoma patients
Interventions
- OTHER F-FDG PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-11-02 |
| Est. Completion | 2022-06-17 |
What the finished NCT03356470 record still lists
NCT03356470 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which F-FDG PET/CT is the first listed.
NCT03356470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03356470 about?
NCT03356470 is a clinical study titled "Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma". This study uses molecular imaging and novel immune monitoring to identify a biomarker of response for melanoma patients receiving immunotherapy with anti-PD-1 immunotherapy. Prior to treatment, FDG and FLT PET/CT will be obtained, together with blood and tumor biopsies from each patient. A follow-up...
What is the current status of trial NCT03356470?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2017-11-02. Estimated completion is 2022-06-17.
What interventions are being tested in trial NCT03356470?
The interventions under investigation include: F-FDG PET/CT (OTHER).
Who is sponsoring clinical trial NCT03356470?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI